Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397037 | 0.79 | DGAT1 (0.47) | DGAT1 | |
| SCHEMBL2145624 | 0.79 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL2390869 | 0.78 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL2393326 | 0.77 | DGAT1 (0.44) | DGAT1ALDH1A1 | |
| SCHEMBL16196893 | 0.76 | HDAC4 (0.48) | HDAC4CKS1BSKP1SKP2USP2 | |
| SCHEMBL2378870 | 0.75 | DGAT1 (0.82) | DGAT1 | |
| SCHEMBL2393695 | 0.75 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL16049350 | 0.73 | CKS1B (0.50) | CKS1BSKP1SKP2USP2SMN1; SMN2 | |
| SCHEMBL2145308 | 0.72 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL15750161 | 0.72 | CNR2 (0.55) | SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716312-B2 | Inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2367598-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885HDAC4 468/4885CKS1B 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.